P&G sales hit by PGT termination
This article was originally published in OTC Bulletin
Executive Summary
Innovation, marketing investments and price increases helped Procter & Gamble’s (P&G’s) Personal Health Care sales grow at a “double digit” rate on an organic basis in its first quarter ended 30 September 2018.
You may also be interested in...
P&G Raises Forecast On Strong First Half, Notes Price Increases As Potential Drag
P&G reports 4% organic growth in its fiscal 2019 Q2, building on a strong Q1 and prompting it to raise full-year organic guidance 1%. CFO Jon Moeller warns, however, possible market volatility and competitor activity related to potential price increases could sink its positive estimate.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.